| abstract |
The present invention relates to the use of cannabidiol (CBD) in the treatment of patients with childhood-onset epilepsy who are concurrently taking one or more antiepileptic drugs, which are mediated via GABA. Body agitation works. Preferably, the AED is stiripentol. Preferably, the CBD used is in the form of a highly purified extract of the Cannabis plant, such that the CBD is present in greater than 98% (w/w) of the total extract, and the other components of the extract are characterized. In particular, the cannabinoid tetrahydrocannabinol (THC) has been substantially removed to levels of no more than 0.15% (w/w), and the propyl analogue of CBD cannabidiol (CBDV) and up to 1% is present. Alternatively, the CBD may be synthetically produced CBD. |